US Patent Issued to Jiangsu Hengrui Medicine, SHANGHAI HENGRUI PHARMACEUTICAL on Feb. 24 for "TGF-beta receptor fusion protein pharmaceutical composition and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,539, issued on Feb. 24, was assigned to Jiangsu Hengrui Medicine Co. Ltd. (Lianyungang, China) and SHANGHAI HENGRUI PHARMACEUTICAL Co. LTD. (Shanghai).

"TGF-beta receptor fusion protein pharmaceutical composition and use thereof" was invented by Chenmin Tian (Shanghai), Hao Li (Shanghai) and Xun Liu (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed in the present disclosure are a TGF-Beta receptor fusion protein pharmaceutical composition and a use thereof. Specifically, the pharmaceutical composition comprises a TGF-Beta receptor fusion protein in a sodium citrate buffer, and the TGF-Beta receptor fusion protein comprises a PD-L1 a...